🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
18,156
Companies
1,062
Drugs tracked
3,187

Quick answer

NovaPharmaNews tracks 18,156 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

186 results for “Air” Clear

  1. Mitapivat

    Agios Netherlands B.V.

    Moderate Hepatic Impairment

    phase 1 small molecule completed

    1 trial

  2. Mobocertinib

    Takeda Pharmaceuticals International AG

    Hepatic Impairment

    phase 1 small molecule completed

    1 trial

  3. Mobocertinib

    Takeda Pharmaceuticals International AG

    Renal Impairment

    phase 1 small molecule completed

    1 trial

  4. NBI-98854 50 mg capsule

    NEUROCRINE BIOSCIENCES INC

    Safety, Tolerability, and PK of NBI-98854 in Hepatically Impaired Subjects

    phase 1 small molecule completed

    1 trial

  5. Nalbuphine ER

    Trevi Therapeutics

    Hepatic Impairment

    phase 1 small molecule completed

    1 trial

  6. Open label, Phase I study to assess and compare the pharmacokinetic parameters after multiple oral administration of stiripentol 1000 mg in renal impaired patients and matching controls with normal renal function

    Biocodex

    Patients with renal impairement

    phase 1 other active

    1 trial

  7. PHARMACOKINETICS OF PETRELINTIDE FOLLOWING ADMINISTRATION TO PARTICIPANTS WITH IMPAIRED HEPATIC FUNCTION

    Zealand Pharma A/S

    Healthy / hepatic impaired volunteers only study to assess PK parameters

    phase 1 other active

    1 trial

  8. Phase I, Open-Label Study to Evaluate the Pharmacokinetics, Safety and Tolerability of BIA 28-6156 in Participants with Varying Degrees of Renal Impairment

    Bial Portela & Companhia S.A.

    Parkinson's disease

    phase 1 other active

    1 trial

  9. Phase Ib Randomised, Placebo-controlled, Double-blind, Multicentre Study to Assess the Effects and Safety of AZD5462 on top of Dapagliflozin in Participants with Heart Failure and Moderate Renal Impairment

    AstraZeneca AB

    Moderate Renal Impairment, Heart Failure

    phase 1 other active

    1 trial

  10. Relacorilant

    CORCEPT THERAPEUTICS INC

    Hepatic Impairment

    phase 1 small molecule completed

    1 trial

  11. SPR206

    Spero Therapeutics

    Renal Impairment

    phase 1 small molecule completed

    1 trial

  12. SSP-004184

    Takeda Pharmaceuticals International AG

    Impaired Renal Function

    phase 1 small molecule completed

    1 trial

  13. SSP-004184

    Takeda Pharmaceuticals International AG

    Hepatic Impairment

    phase 1 small molecule completed

    1 trial

  14. Sativex

    Jazz Pharmaceuticals Ireland Limited

    Hepatic Impairment

    phase 1 small molecule completed

    1 trial

  15. Sotagliflozin

    LEXICON PHARMACEUTICALS, INC.

    Renal Impairment

    phase 1 small molecule completed

    1 trial

  16. Soticlestat

    Takeda Pharmaceuticals International AG

    Hepatic Impairment

    phase 1 small molecule completed

    1 trial

  17. Study to Evaluate the PK and Safety of Oral Decitabine and Cedazuridine in Cancer Patients with Hepatic Impairment

    Taiho Pharma Netherlands B.V.

    Solid tumor, Acute myeloid lymphoma (AML), Myelodysplastic syndrome (MDS)

    phase 1 other active

    1 trial

  18. Study to Evaluate the PK and Safety of Oral Decitabine and Cedazuridine in Cancer Patients with Renal Impairment

    Taiho Pharma Netherlands B.V.

    Acute myeloid lymphoma (AML), myelodysplastic syndrome (MDS), or solid tumors

    phase 1 other active

    1 trial

  19. TAK-272

    Takeda Pharmaceuticals International AG

    Renal Impairment

    phase 1 small molecule completed

    1 trial

  20. TAK-279

    Takeda Pharmaceuticals International AG

    Hepatic Impairment

    phase 1 small molecule completed

    1 trial

  21. TAK-279

    Takeda Pharmaceuticals International AG

    Renal Impairment

    phase 1 small molecule completed

    1 trial

  22. TAK-954

    Takeda Pharmaceuticals International AG

    Renal Impairment

    phase 1 small molecule completed

    1 trial

  23. TAK-954

    Takeda Pharmaceuticals International AG

    Hepatic Impairment

    phase 1 small molecule completed

    1 trial

  24. TD-4208

    Theravance Biopharma Ireland Umited

    Hepatic Impairment

    phase 1 small molecule completed

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 18,156 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources